Review





Similar Products

hydroxy 9z 11e octadecadienoic acid 13s and 13r hode  (Larodan)
90
Larodan hydroxy 9z 11e octadecadienoic acid 13s and 13r hode
Hydroxy 9z 11e Octadecadienoic Acid 13s And 13r Hode, supplied by Larodan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/13(R)-hydroxy-9(Z)%2C11(E)-octadecadienoic+acid/pm41242694-86-10-32
Average 90 stars, based on 1 article reviews
hydroxy 9z 11e octadecadienoic acid 13s and 13r hode - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
13 hode  (Proteintech)
93
Proteintech 13 hode
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
13 Hode, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/Human+ANGPTL4+ELISA+Kit/pmc12829093-326-19-24
Average 93 stars, based on 1 article reviews
13 hode - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
13(s)-hode-d4 standard  (Cayman Chemical)
90
Cayman Chemical 13(s)-hode-d4 standard
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
13(s) Hode D4 Standard, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/13+hode+d4/pmc12272432-37-48-73
Average 90 stars, based on 1 article reviews
13(s)-hode-d4 standard - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
hode: 9(s)-hydroxy-octadecadienoic acid-d4  (Cayman Chemical)
90
Cayman Chemical hode: 9(s)-hydroxy-octadecadienoic acid-d4
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
Hode: 9(s) Hydroxy Octadecadienoic Acid D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/taurocholic+acid+d4/bio_rxiv__2025__06__11__659216-217-34-50
Average 90 stars, based on 1 article reviews
hode: 9(s)-hydroxy-octadecadienoic acid-d4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
hode: 13(s)-hydroxy-octadecadienoic acid-d4  (Cayman Chemical)
90
Cayman Chemical hode: 13(s)-hydroxy-octadecadienoic acid-d4
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
Hode: 13(s) Hydroxy Octadecadienoic Acid D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/taurocholic+acid+d4/bio_rxiv__2025__06__11__659216-217-37-50
Average 90 stars, based on 1 article reviews
hode: 13(s)-hydroxy-octadecadienoic acid-d4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
13(s)-hode-d4  (Cayman Chemical)
90
Cayman Chemical 13(s)-hode-d4
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
13(s) Hode D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/13+hode+d4/pm40490052-75-45-60
Average 90 stars, based on 1 article reviews
13(s)-hode-d4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
13(s)-hode gc19463  (GlpBio Technology Inc)
90
GlpBio Technology Inc 13(s)-hode gc19463
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
13(s) Hode Gc19463, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/13+s++hode+gc19463/pmc12162603-94-0-2
Average 90 stars, based on 1 article reviews
13(s)-hode gc19463 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
9(s)-hode-d4  (Cayman Chemical)
90
Cayman Chemical 9(s)-hode-d4
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
9(s) Hode D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/13+hode+d4/pm40306479-61-8-18
Average 90 stars, based on 1 article reviews
9(s)-hode-d4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
hode  (Thermo Fisher)
90
Thermo Fisher hode
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
Hode, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/pm40073602-29-16-12
Average 90 stars, based on 1 article reviews
hode - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
9-hode  (Cayman Chemical)
90
Cayman Chemical 9-hode
PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
9 Hode, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hode/9+hode/pm40044852-489-96-99
Average 90 stars, based on 1 article reviews
9-hode - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5

Journal: Molecular Cancer

Article Title: Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma

doi: 10.1186/s12943-025-02516-2

Figure Lengend Snippet: PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5

Article Snippet: Blood samples were collected from cardiac puncture separated by centrifugation at 3000 g, 4°C, 10 min. OxLDL (Elabscience, E-EL-M0066), 13-HODE (MEIMIAN, MM-60095H2) and ANGPTL4 (Proteintech, KE00186) levels were measured using ELISA kits following the manufacturer’s instructions.

Techniques: Activity Assay, Expressing, Quantitative RT-PCR, Biomarker Discovery, Western Blot, Knockdown, ChIP-qPCR, Binding Assay, Enzyme-linked Immunosorbent Assay, Ligand Binding Assay, Co-Immunoprecipitation Assay